Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells

PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusovici, Raluca, Sakhalkar, Monali, Chalam, Kakarla V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/
https://www.ncbi.nlm.nih.gov/pubmed/22219629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/
https://www.ncbi.nlm.nih.gov/pubmed/22219629

Ejemplares similares